Abstract
Alzheimer’s disease (AD) is an enormous healthcare challenge, and 50 million people are currently suffering from it. There are several pathophysiological mechanisms involved, but cholinesterase inhibitors remained the major target from the last 2–3 decades. Among four available therapeutics (donepezil, rivastigmine, galantamine, and memantine), three of them are cholinesterase inhibitors. Herein, we describe the role of acetylcholine sterase (AChE) and related hypothesis in AD along with the pharmacological and chemical aspects of the available cholinesterase inhibitors. This chapter discusses the development of several congeners and hybrids of available cholinesterase inhibitors along with their binding patterns in enzyme active sites.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Whitehouse PJ, Price DL, Struble RG et al (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237–1239
Patterson C (2018) In: World Alzheimer report 2018. The state of the art of dementia research: new frontiers. London, pp 32–36
Cuijpers Y, Van Lente H (2015) Early diagnostics and Alzheimer’s disease: beyond ‘cure’ and ‘care’. Technol Forecast Soc Change 93:54–67
Hippius H, Neundörfer G (2003) The discovery of Alzheimer’s disease. Dialogues Clin Neurosci 5:101
Forsyth E, Ritzline PD (1998) An overview of the etiology, diagnosis, and treatment of Alzheimer disease. Phys Ther 78:1325–1331
Gold CA, Budson AE (2008) Memory loss in Alzheimer’s disease: implications for development of therapeutics. Expert Rev Neurother 8:1879–1891
Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184
Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 16:460–465
Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 23:134–147
Bartus RT, Dean RR, Beer B et al (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414
Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 104:1433–1439
Qu T, Manev R, Manev H (2001) 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 13:304–305
Cole SL, Vassar R (2007) The Alzheimer’s disease β-secretase enzyme, BACE1. Mol Neurodegener 2:22
Talesa VN (2001) Acetylcholinesterase in Alzheimer’s disease. Mech Ageing Dev 122:1961–1969
Shrivastava SK, Sinha SK, Srivastava P et al (2019) Design and development of novel p-aminobenzoic acid derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer’s disease. Bioorg Chem 82:211–223
Srivastava P, Tripathi PN, Sharma P et al (2019) Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur J Med Chem 163:116–135
Tripathi PN, Srivastava P, Sharma P et al (2018) Biphenyl-3-oxo-1, 2, 4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem 85:82–96
Kumar M, Sharma P, Maheshwari R et al (2018) Beyond the blood–brain barrier: facing new challenges and prospects of nanotechnology-mediated targeted delivery to the brain. In: Nanotechnology-based targeted drug delivery systems for brain tumors. Elsevier, pp 397–437
Shrivastava SK, Srivastava P, Upendra T et al (2017) Design, synthesis and evaluation of some N-methylenebenzenamine derivatives as selective acetylcholinesterase (AChE) inhibitor and antioxidant to enhance learning and memory. Biorg Med Chem 25:1471–1480
Sinha SK, Shrivastava SK (2013) Synthesis, evaluation and molecular dynamics study of some new 4-aminopyridine semicarbazones as an antiamnesic and cognition enhancing agents. Biorg Med Chem 21:5451–5460
Sinha SK, Shrivastava SK (2013) Design, synthesis and evaluation of some new 4-aminopyridine derivatives in learning and memory. Bioorg Med Chem Lett 23:2984–2989
Sinha SK, Shrivastava SK (2012) Synthesis and evaluation of some new 4-aminopyridine derivatives as a potent antiamnesic and cognition enhancing drugs. Med Chem Res 21:4395–4402
Tripathi PN, Srivastava P, Sharma P et al (2019) Design and development of novel N-(pyrimidin-2-yl)-1, 3, 4-oxadiazole hybrids to treat cognitive dysfunctions. Biorg Med Chem 27:1327–1340
Rosini M, Simoni E, Minarini A et al (2014) Multi-target design strategies in the context of Alzheimer’s disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem Res 39:1914–1923
Rosini M, Simoni E, Bartolini M et al (2008) Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer’s disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem 51:4381–4384
Hogan DB (2007) Progress update: pharmacological treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat 3:569
Sharma P, Srivastava P, Seth A et al (2019) Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol 174:53–89
Davies P, Maloney A (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 308:1403
Thompson P, Wright D, Counsell CE et al (2012) Statistical analysis, trial design and duration in Alzheimer’s disease clinical trials: a review. Int Psychogeriatr 24:689–697
Hebb C (1972) Biosynthesis of acetylcholine in nervous tissue. Physiol Rev 52:918–957
Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495–529
Lanctôt KL, Herrmann N, Yau KK et al (2003) Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Can Med Assoc J 169:557–564
Taylor P (1998) Development of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease. Neurology 51:S30–S35
Pezzementi L, Nachon F, Chatonnet A (2011) Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: an atypical butyrylcholinesterase from the Medaka Oryzias latipes. PLoS One 6:e17396
Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131
Behra M, Cousin X, Bertrand C et al (2002) Acetylcholinesterase is required for neuronal and muscular development in the zebrafish embryo. Nat Neurosci 5:111
Darvesh S, Cash MK, Reid GA et al (2012) Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 71:2–14
Cousin X, Hotelier T, Giles K et al (1998) aCHEdb: the database system for ESTHER, the α/β fold family of proteins and the Cholinesterase gene server. Nucleic Acids Res 26:226–228
Holzgrabe U, Kapková P, Alptüzün V et al (2007) Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 11:161–179
Nicolet Y, Lockridge O, Masson P et al (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278:41141–41147
Moral-Naranjo MT, Cabezas-Herrera J, Campoy FJ et al (1997) Glycosylation of cholinesterase forms in brain from normal and dystrophic Lama2dy mice. Neurosci Lett 226:45–48
Saxena A, Redman AM, Jiang X et al (1997) Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 36:14642–14651
Kryger G, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept®): implications for the design of new anti-Alzheimer drugs. Structure 7:297–307
Almeida JSD, Cavalcante SFDA, Dolezal R et al (2019) Molecular modeling studies on the interactions of aflatoxin B1 and its metabolites with the peripheral anionic site (PAS) of human acetylcholinesterase. J Biomol Struct Dyn 37(8):2041–2048
Inestrosa NC, Alvarez A, Perez CA et al (1996) Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881–891
Zhang Y, Kua J, Mccammon JA (2002) Role of the catalytic triad and oxyanion hole in acetylcholinesterase catalysis: an ab initio QM/MM study. J Am Chem Soc 124:10572–10577
Ordentlich A, Barak D, Kronman C et al (1998) Functional characteristics of the oxyanion hole in human acetylcholinesterase. J Biol Chem 273:19509–19517
Bajda M, Więckowska A, Hebda M et al (2013) Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci 14:5608–5632
Whitehead A, Perdomo C, Pratt RD et al (2004) Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 19:624–633
Sharma P, Tripathi A, Tripathi PN et al (2019) Design and development of multitarget-directed N-benzylpiperidine analogs as potential candidates for the treatment of Alzheimer’s disease. Eur J Med Chem 167:510–524
Camps P, Formosa X, Galdeano C et al (2008) Novel donepezil-based inhibitors of acetyl-and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation. J Med Chem 51:3588–3598
Kume T, Sugimoto M, Takada Y et al (2005) Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol 527:77–85
Tiseo P, Rogers S, Friedhoff L (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 46:13
Sugimoto H, Ogura H, Arai Y et al (2002) Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 89:7–20
Sugimoto H, Yamanish Y, Iimura Y et al (2000) Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 7:303–339
Andreani A, Cavalli A, Granaiola M et al (2001) Synthesis and screening for Antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene) methylindoles and-pyrroles related to donepezil. J Med Chem 44:4011–4014
Contreras J-M, Rival YM, Chayer S et al (1999) Aminopyridazines as acetylcholinesterase inhibitors. J Med Chem 42:730–741
Omran Z, Cailly T, Lescot E et al (2005) Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil. Eur J Med Chem 40:1222–1245
Więckowska A, Więckowski K, Bajda M et al (2015) Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Biorg Med Chem 23:2445–2457
Shidore M, Machhi J, Shingala K et al (2016) Benzylpiperidine-linked diarylthiazoles as potential anti-Alzheimer’s agents: synthesis and biological evaluation. J Med Chem 59:5823–5846
Costanzo P, Cariati L, Desiderio D et al (2016) Design, synthesis, and evaluation of donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Med Chem Lett 7:470–475
Caliandro R, Pesaresi A, Cariati L et al (2018) Kinetic and structural studies on the interactions of Torpedo californica acetylcholinesterase with two donepezil-like rigid analogues. J Enzyme Inhib Med Chem 33:794–803
Villarroya M, García AG, Marco-Contelles J et al (2007) An update on the pharmacology of galantamine. Expert Opin Investig Drugs 16:1987–1998
Heinrich M, Teoh HL (2004) Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J Ethnopharmacol 92:147–162
Maelicke A, Samochocki M, Jostock R et al (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 49:279–288
Farlow MR (2003) Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 42:1383–1392
Cheung J, Rudolph MJ, Burshteyn F et al (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 55:10282–10286
Fang L, Fang X, Gou S et al (2014) Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents. Eur J Med Chem 76:376–386
Guzior N, Wieckowska A, Panek D et al (2015) Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr Med Chem 22:373–404
Atanasova M, Yordanov N, Dimitrov I et al (2015) Molecular docking study on galantamine derivatives as cholinesterase inhibitors. Mol Inform 34:394–403
Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 20:634–647
Gottwald MD, Rozanski RI (1999) Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status. Expert Opin Investig Drugs 8:1673–1682
Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719–739
Bolognesi ML, Bartolini M, Cavalli A et al (2004) Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 47:5945–5952
Wang L, Wang Y, Tian Y et al (2017) Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors. Biorg Med Chem 25:360–371
Crismon ML (1994) Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother 28:744–751
Pohanka M (2011) Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Palacky Univ Olomouc 155(3):219–229
Harel M, Schalk I, Ehret-Sabatier L et al (1993) Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A 90:9031–9035
Blackard WG Jr, Sood GK, Crowe DR et al (1998) Tacrine: a cause of fatal hepatotoxicity? J Clin Gastroenterol 26:57–59
Pessayre D, Mansouri A, Haouzi D et al (1999) Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 15:367–373
Lagadic-Gossmann D, Rissel M, Le Bot M et al (1998) Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell Biol Toxicol 14:361–373
Tumiatti V, Minarini A, Bolognesi M et al (2010) Tacrine derivatives and Alzheimer’s disease. Curr Med Chem 17:1825–1838
Minarini A, Milelli A, Tumiatti V et al (2012) Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment. Neuropharmacology 62:997–1003
Recanatini M, Cavalli A, Belluti F et al (2000) SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J Med Chem 43:2007–2018
Tang H, Zhao L-Z, Zhao H-T et al (2011) Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors. Eur J Med Chem 46:4970–4979
Mao F, Huang L, Luo Z et al (2012) O-hydroxyl-or o-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-β aggregation. Biorg Med Chem 20:5884–5892
Jin H, Nguyen T, Go M (2014) Acetylcholinesterase and butyrylcholinesterase inhibitory properties of functionalized tetrahydroacridines and related analogs. Med Chem (Los Angeles) 4(10):688–696
Nepovimova E, Korabecny J, Dolezal R et al (2015) Tacrine–trolox hybrids: a novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J Med Chem 58:8985–9003
Quintanova C, Keri RS, Marques SM et al (2015) Design, synthesis and bioevaluation of tacrine hybrids with cinnamate and cinnamylidene acetate derivatives as potential anti-Alzheimer drugs. MedChemComm 6:1969–1977
Sameem B, Saeedi M, Mahdavi M et al (2017) A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease. Eur J Med Chem 128:332–345
Small G, Bullock R (2011) Defining optimal treatment with cholinesterase inhibitors in Alzheimer’s disease. Alzheimers Dement 7:177–184
Gauthier S (2001) Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer’s disease. Drugs Aging 18:853–862
Jiang S, Li Y, Zhang C et al (2014) M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neurosci Bull 30:295–307
Maelicke A, Albuquerque EX (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer’s disease. Eur J Pharmacol 393:165–170
Korabecny J, Andrs M, Nepovimova E et al (2015) 7-Methoxytacrine-p-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer’s disease treatment. Molecules 20:22084–22101
Ceschi MA, Da Costa JS, Lopes JPB et al (2016) Novel series of tacrine-tianeptine hybrids: synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach. Eur J Med Chem 121:758–772
Zha X, Lamba D, Zhang L et al (2015) Novel tacrine–benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, biological evaluation, and X-ray crystallography. J Med Chem 59:114–131
Benek O, Soukup O, Pasdiorova M et al (2016) Design, synthesis and in vitro evaluation of indolotacrine analogues as multitarget-directed ligands for the treatment of Alzheimer’s disease. ChemMedChem 11:1264–1269
Keri RS, Quintanova C, Chaves S et al (2016) New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer’s disease. Chem Biol Drug Des 87:101–111
Najafi Z, Mahdavi M, Saeedi M et al (2017) Novel tacrine-1,2,3-triazole hybrids: in vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors. Eur J Med Chem 125:1200–1212
Jeřábek J, Uliassi E, Guidotti L et al (2017) Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer’s disease. Eur J Med Chem 127:250–262
Spilovska K, Korabecny J, Sepsova V et al (2017) Novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer’s agents: design, synthesis and biological evaluation. Molecules 22:1006
Chioua M, Buzzi E, Moraleda I et al (2018) Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer’s disease. Eur J Med Chem 155:839
Lopes JPB, Silva L, Da Costa Franarin G et al (2018) Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives. Biorg Med Chem 26:5566–5577
Chand K, Candeias E, Cardoso SM et al (2018) Tacrine–deferiprone hybrids as multi-target-directed metal chelators against Alzheimer’s disease: a two-in-one drug. Metallomics 10:1460–1475
Cheng Z-Q, Zhu K-K, Zhang J et al (2019) Molecular-docking-guided design and synthesis of new IAA-tacrine hybrids as multifunctional AChE/BChE inhibitors. Bioorg Chem 83:277–288
Lu C, Zhou Q, Yan J et al (2013) A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease. Eur J Med Chem 62:745–753
Fang L, Appenroth D, Decker M et al (2008) Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J Med Chem 51:713–716
Rosini M, Andrisano V, Bartolini M et al (2005) Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 48:360–363
Thiratmatrakul S, Yenjai C, Waiwut P et al (2014) Synthesis, biological evaluation and molecular modeling study of novel tacrine–carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem 75:21–30
FernáNdez-Bachiller MI, PéRez CN, Monjas L et al (2012) New tacrine–4-oxo-4 H-chromene hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J Med Chem 55:1303–1317
Rodríguez-Franco MI, Fernández-Bachiller MI, Pérez C et al (2006) Novel tacrine−melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 49:459–462
Acknowledgments
The authors are thankful to Department of Health Research (DHR), Ministry of Health and Family Welfare (MHFW), Government of India, New Delhi for providing Young Scientist grant to Mr. Piyoosh Sharma in newer areas of Drug Chemistry (25011/215-HRD/2016-HR).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Sharma, P., Tripathi, M.K., Shrivastava, S.K. (2020). Cholinesterase as a Target for Drug Development in Alzheimer’s Disease. In: Labrou, N. (eds) Targeting Enzymes for Pharmaceutical Development. Methods in Molecular Biology, vol 2089. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0163-1_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0163-1_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0162-4
Online ISBN: 978-1-0716-0163-1
eBook Packages: Springer Protocols